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Incidence of stroke after myocardial infarction
Evidence presented from a recent community-based cohort designed study by Witt
and colleagues (2005) suggests that the risk of stroke substantially increases following
myocardial infarction (MI). While this suggestion is not new, this particular study
was longitudinal in design, spanning a period of 2 decades with a median follow-up
of 5.6 years (range 0 to 22.2 years). The study was somewhat limited as the cohort
under investigation comprised a white population specific to Olmsted County, MN, USA
and the measured outcome included only a review of medical records. Notwithstanding
these limitations, the study provides some quite interesting epidemiological information
regarding the incidence of stroke following MI (Witt et al 2005).
Epidemiological studies have demonstrated a link between coronary artery disease
and stroke (Heyman et al 1980; Visser et al 1985; Rose 1989) with the association
between coronary artery disease, MI and stroke being ascribed to a common
pathophysiology, atherosclerosis (Hess et al 1993). Interestingly, prior to the era of
thrombolytic and anticoagulation therapy, the incidence of stroke reported was
approximately 2.4% in patients with acute MI (Thompson and Robinson 1978;
Komrad et al 1984) with intracranial hemorrhage being quite a rare event. In the
current climate in which thrombolytics and anticoagulants are employed in patients
with MI, the incidence of nonhemorrhagic stroke seems to be less than 1.4%, whereas
intracranial hemorrhage is reported as 1.6% or less (O’Connor et al 1990; Maggioni
et al 1991; Longstreth et al 1993; Gore et al 1995). Views have been expressed that
thrombolytic, anticoagulant, and antiplatelet therapy may be helpful in reducing the
incidence of stroke (Mahaffey et al 1998; Chen et al 2005), but strong evidence in
support of this view is not that apparent.
In the study by Witt and colleagues (2005) a marked increase in the incidence of
stroke was found within 30 day post-MI. This amounted to a 44-fold (95% confidence
interval [CI], 32 to 59) increase in the incidence of stroke in patients with MI when
compared with the rate of stroke in the general population. A sharp decline followed
thereafter in the incidence of stroke to 3.1-fold (95% CI, 2.0 to 4.5) within 31 days to
one year. Furthermore, the rate of stroke following MI stabilized within 3–4 years
(standardized morbidity ration being 1.6, 95% CI, 0.9 to 2.8), which was no different
than in the general population for that region (Witt et al 2005).
Univariate analysis indicated that there is a higher risk of stroke following MI in
older patients (p < 0.001), women (p < 0.001), diabetics (p < 0.001), hypertensives
(p < 0.001), and those with previous history of stroke (p < 0.001) to mention some
sub-groups. However, hyperlipidemia (p = 0.114) did not appear to be associated
with a higher incidence of stroke after MI. It is assumed that vascular problems are a
major contributor to vascular mortality, but surprisingly the evidence in this particular
study does not strongly link the incidence of stroke after MI in patients with
hyperlipidemia. While cardiovascular risk factors such as diabetes (p < 0.001) was
found to be also independently associated with higher risk of stroke in this population,
hypertension was not reported as an independent risk factor in the population studied.
Older age (p < 0.001) and previous history of stroke (p < 0.001) were also reported as
independent risk factors (Witt et al 2005).
There appears to be a significant (p = 0.002) increase in the risk of stroke after MI
in patients on warfarin (relative risk [RR] 1.7, 95% CI, 1.22–2.36), whereas thereVascular Health and Risk Management 2006:2(1) 2
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was no significant increase in the incidence of stroke in
patients on thrombolytics (p = 0.39), aspirin (p = 0.41), low-
molecular weight heparin (p = 0.40), or antiplatelet agents
(p = 0.36). The difference between warfarin and other agents
that affect blood physiology may relate to its complex
pharmacokinetics and could possibly be associated with an
increase in incidence of hemorrhagic stroke. Of the 273
strokes recorded in the population studied, 13 (5%) were
due to intracerebral hemorrhage and 1 was subarachnoid,
but it was not apparent if these patients were being treated
with warfarin. Furthermore, it appears that a significantly
(p < 0.001) higher occurrence of strokes following MI in
patients on diuretics (RR 1.82, 95% CI, 1.42–2.33). Whether
this observation is related to the use of diuretic agents or
linked to the type of patients on diuretics remains unclear
(Witt et al 2005).
While the study by Witt and colleagues (2005) does
provide a unique perspective on the incidence of stroke after
MI over 2 decades, the authors indicated some shortcomings
such as its observational nature and the fact that data review
did not permit for the determination of whether anticoagulant
or antiplatelet medications were prescribed to treat or prevent
stroke after MI, clearly limiting conclusions on the use of
such medications and the risk of stroke. This study can
perhaps set the foundation for future studies to assess the
impact of anticoagulant and antiplatelet medications on the
occurrence of stroke following MI in longitudinal design
as well as in a less homogenous population.
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